Publications

484 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Advice on a potential candidate for conditional inclusion of larotrectinib (Vitrakvi®) for solid tumours with NTRK gene fusion

    Zorginstituut Nederland recommends that larotrectinib should be designated as a potential candidate for conditional inclusion. ...

    Letter | 10-03-2021

  2. GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups

    The National Health Care Institute has completed its assessment whether 13-valent pneumococcal conjugate vaccine (PVC13; ...

    Report | 03-03-2021

  3. GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

    The National Health Care Institute has completed its assessment whether Brimonidine Stulln 2mg/ml eye drop solution, single-use ...

    Report | 24-02-2021

  4. GVS assessment of formoterol/ glycopyrronium/ budesonide (Trixeo® aerosphere)

    The National Health Care Institute has completed its assessment whether the product formoterol/glycopyrronium/budesonide (Trixeo® ...

    Report | 22-02-2021

  5. GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia

    The National Health Care Institute has completed its assessment whether sodium zirconium cyclosilicate (Lokelma®) is ...

    Report | 12-02-2021

  6. Package advice multiple myeloma

    Several combination therapies that are used to treat multiple myelomain are placed in the lock procedure for expensive medicinal ...

    Report | 11-02-2021

  7. GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease

    The National Health Care Institute has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product ...

    Report | 03-02-2021

  8. GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria

    The National Health Care Institute has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product ...

    Report | 02-02-2021

  9. GVS assessment oxybutynin intravesical solution (Vesolox®)

    Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...

    Report | 18-01-2021

  10. GVS advice mexiletine (Namuscla®)

    The National Health Care Institute has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable ...

    Report | 13-01-2021